Portal de investigación
A Randomized Phase 2 Study of Ocular Toxicity Evaluation and Mitigation During Treatment with Mirvetuximab Soravtansine in Patients with Recurrent Ovarian Cancer with High Folate Receptor-Alpha Expression.
Datos básicos
Documentos
- No hay documentos
Grupos
Financiadores - Promotores
IMMUNOGEN, INC.
Cita
A Randomized Phase 2 Study of Ocular Toxicity Evaluation and Mitigation During Treatment with Mirvetuximab Soravtansine in Patients with Recurrent Ovarian Cancer with High Folate Receptor-Alpha Expression. (IMGN853-0424). IMMUNOGEN, INC. 2025IP:HELENA DE LA CUEVA SAPIÑA,ANA SANTABALLA BERTRÁN.